# EDGAR Filing Document

**Accession Number:** 0001460702
**File Stem:** 0001213900-25-112721
**Filing Date:** 2025-11
**Character Count:** 9643
**Document Hash:** 8328e8167e113b1f8dff22fa3a2ca674
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-112721.hdr.sgml**: 20251119

**ACCESSION NUMBER**: 0001213900-25-112721

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D/A

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251119

**DATE AS OF CHANGE**: 20251119

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Qualigen Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001460702
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 263474527
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-88903
- **FILM NUMBER:** 251500222

**BUSINESS ADDRESS:**
- **STREET 1:** 2042 CORTE DEL NOGAL
- **STREET 2:** CARLSBAD
- **CITY:** CALIFORNIA
- **STATE:** CA
- **ZIP:** 92011
- **BUSINESS PHONE:** (760) 918-9165

**MAIL ADDRESS:**
- **STREET 1:** 2042 CORTE DEL NOGAL
- **STREET 2:** CARLSBAD
- **CITY:** CALIFORNIA
- **STATE:** CA
- **ZIP:** 92011

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RITTER PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20090402
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** FARADAY FUTURE INTELLIGENT ELECTRIC INC.
- **CENTRAL INDEX KEY:** 0001805521
- **STANDARD INDUSTRIAL CLASSIFICATION:** MOTOR VEHICLES & PASSENGER CAR BODIES [3711]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 844720320
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D/A

**BUSINESS ADDRESS:**
- **STREET 1:** 654 MADISON AVENUE, SUITE 1009
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10065
- **BUSINESS PHONE:** 646 502 9845

**MAIL ADDRESS:**
- **STREET 1:** 654 MADISON AVENUE, SUITE 1009
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10065

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Property Solutions Acquisition Corp.
- **DATE OF NAME CHANGE:** 20200304

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**(Amendment No. 1)**

**QUALIGEN THERAPEUTICS, INC.**

*(Name of Issuer)*

**Common Stock, par value $0.001 per share**

*(Title of Class of Securities)*

**74754R103**

*(CUSIP Number)*

**Jiawei Wang**<br>18455 S. Figueroa Street<br>Gardena CA 90248<br>(424) 276-7616

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**11/17/2025**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **74754R103** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**FARADAY FUTURE INTELLIGENT ELECTRIC INC.** | Name of reporting person<br>**FARADAY FUTURE INTELLIGENT ELECTRIC INC.** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**WC** | Source of funds (See Instructions)<br>**WC** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**CALIFORNIA** | Citizenship or place of organization<br>**CALIFORNIA** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1227147.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1227147.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1227147.00** | Aggregate amount beneficially owned by each reporting person<br>**1227147.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**19.99%** | Percent of class represented by amount in Row (11)<br>**19.99%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**CO** | Type of Reporting Person (See Instructions)<br>**CO** | |

---

**Comment for Reporting Person:** The amounts reported herein do not include 4,857,728 shares of Common Stock (as defined in Item 1) that are issuable upon the conversion of Series B Preferred Stock (as defined in Item 3) but which are subject to a 19.99% beneficial ownership limitation.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.001 per share

**(b) Name of Issuer:**
QUALIGEN THERAPEUTICS, INC.

**(c) Address of Issuer's Principal Executive Offices:**
5857 Owens Avenue, Suite 300, Carlsbad, CA, 92008

**Item 4. Purpose of Transaction**

The Reporting Person is filing this First Amendment to report that it has acquired beneficial ownership of shares of Common Stock issuable upon the conversion of shares of Series B Preferred Stock that were purchased pursuant to the Subscription Agreement but which were not convertible until the receipt of the approval of the Issuer's stockholders, which approval was obtained on November 12, 2025, as reported on the Issuer's Form 8-K filed with the Securities and Exchange Commission on November 17, 2025. The Reporting Person may, from time to time, depending on prevailing market, economic and other conditions, acquire additional shares of Common Stock or other securities of the Issuer, dispose of any such securities, or engage in discussions with the Issuer concerning such acquisitions or dispositions or further investments in the Issuer.

The Reporting Person also entered into a Lead Investor Agreement with the Issuer on September 19, 2025, pursuant to which the Issuer agreed to appoint members of its board of directors and certain officers designated by the Reporting Person upon the closing of the transactions contemplated by the Subscription Agreement (the "Lead Investor Agreement"). A copy of the Lead Investor Agreement was filed with the Original Schedule 13D as Exhibit 2.

The Reporting Person intends to review its investment in the Issuer on a continuing basis and may decide at any time to increase the size of its investment in the Issuer in the open market, in privately negotiated transactions or otherwise.

The Reporting Person has no present plan or proposal that relates to or would result in any other action specified in clauses (a) through (j) of Item 4 of Schedule 13D except as set forth herein or such as would occur upon or in connection with completion of, or following, any of the actions discussed herein.

**Item 5. Interest in Securities of the Issuer**

**(a)**
As of the date hereof, the Reporting Person beneficially owns an aggregate of 1,227,147 shares of Common Stock, representing approximately 19.99% of the outstanding shares of Common Stock (based upon (i) 5,160,383 shares of Common Stock issued and outstanding as of November 14, 2025, as reported in the Issuer's Form 10-Q filed with the Securities and Exchange Commission on November 14, 2025, plus (ii) 1,227,147 shares of Common Stock issuable upon the conversion of the Series B Preferred Stock). All of the shares of Common Stock beneficially owned by the Reporting Person are held directly by the Reporting Person.

**(b)**
All of the shares reported in this First Amendment are held directly by the Reporting Person.

**(c)**
Except as set forth in this First Amendment, the Reporting Person has not effected any transactions in the Issuer's Common Stock during the 60 days preceding the date of this First Amendment.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

In connection with the Subscription Agreement, the Reporting Person entered into a Registration Rights Agreement with the Issuer, on September 19, 2025, pursuant to which the Issuer agreed to file a registration statement with the Securities and Exchange Commission to register for resale certain securities of the Issuer, including the Shares, upon the fulfillment of certain conditions described therein (the "Registration Rights Agreement"). A copy of the form of the Registration Rights Agreement was filed with the Original Schedule 13D as Exhibit 3.

Except as set forth in this First Amendment, there are no contracts, arrangements, understandings or relationships (legal or otherwise) between the Reporting Person and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any other securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, divisions of profits or loss, or the giving or withholding of proxies, including any securities pledged or otherwise subject to a contingency the occurrence of which would give another person voting power or investment power over such securities.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** FARADAY FUTURE INTELLIGENT ELECTRIC INC.

**Signature:** /s/ Jiawei Wang

**Name/Title:** Global President

**Date:** 11/19/2025